Codexis (CDXS) Cash from Financing Activities (2010 - 2026)
Codexis' (CDXS) quarterly Cash from Financing Activities came in at -$14000.0 in Q1 2026, down 101.29% year-on-year from $1.1 million in Q1 2025, and down 107.78% quarter-over-quarter from $180000.0 in Q4 2025.
Codexis (CDXS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Codexis' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$14000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 101.29% year-over-year to -$14000.0 in Q1 2026; TTM through Mar 2026 was $26.8 million, a 17.0% decrease from a year earlier, with the FY2025 full-year figure at $27.9 million, down 53.85% from the prior year.
- Cash from Financing Activities eased to -$14000.0 in Q1 2026 per CDXS's latest filing, from $180000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $30.3 million in Q3 2024 and bottomed at -$1.3 million in Q1 2022.
- The 5-year median for Cash from Financing Activities is $286000.0 (2022), against an average of $6.0 million.
- Across the five-year window, Cash from Financing Activities plunged 7629.41% in 2022 and soared 28161.11% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $339000.0 in 2022, then slumped by 131.86% to -$108000.0 in 2023, then surged by 1148.15% to $1.1 million in 2024, then tumbled by 84.1% to $180000.0 in 2025, then tumbled by 107.78% to -$14000.0 in 2026.
- Per Business Quant, the three latest CDXS Cash from Financing Activities figures stand at -$14000.0 (Q1 2026), $180000.0 (Q4 2025), and -$111000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Codexis | 180.63 Mn | 115.49 Mn | 13.18 Mn | -14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,000.00 |
| Mar 31, 2026 | -14,000.00 |
| Dec 31, 2025 | 180,000.00 |
| Dec 31, 2025 | 180,000.00 |
| Sep 30, 2025 | -111,000.00 |
| Sep 30, 2025 | -111,000.00 |
| Jun 30, 2025 | 26.77 Mn |
| Jun 30, 2025 | 26.77 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 30.31 Mn |
| Sep 30, 2024 | 30.31 Mn |
| Jun 30, 2024 | -197,000.00 |
| Jun 30, 2024 | -197,000.00 |
| Mar 31, 2024 | 29.28 Mn |
| Mar 31, 2024 | 29.28 Mn |
| Sep 30, 2023 | -108,000.00 |
| Sep 30, 2023 | -108,000.00 |